CTOs on the Move

Massachusetts Medical Society

www.massmed.org

 
The Massachusetts Medical Society is the oldest, most distinguished and prestigious continuously operating state medical association in the United States and the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.massmed.org
  • 860, Winter Street
    Waltham, MA USA 02451
  • Phone: 800.322.2303

Executives

Name Title Contact Details
Jacqui Boire
Director, Technology Strategy and Planning Profile

Similar Companies

Meda

Meda is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

APS Pharmacy

APS Pharmacy is a Palm Harbor, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VoCare

The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...

Elixir

Elixir, (formerly EnvisionRxOptions) a wholly owned subsidiary of Rite Aid, is a pharmacy benefits and services company with the unique ability to optimize the full pharmacy care experience.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.